Examinations with Anteovin, a biphasic contraceptive.

The clinical trial of Anteovin a biphasic contraceptive was included in the advisory program of the Mother Care Centre in Budapest Hungary. Parallel with Anteovin treatment 1 Ovidon-treated group and another Rigevidon-treated group also were evaluated as controls to assess the differences. Anteovin was given to 109 women; 2 did not appear at the control examination. Ovidon was given to 59 women and Rigevidon to 77 women. Pregnancy did not occur during the consumption of any of the tablets. The use of Anteovin was not discontinued for health reasons or side effects by any of the women; Ovidon was discontinued by 10 women and Rigevidon by 9 women the former for weight gain and vaginal discharge and the latter for breakthrough bleeding. Anteovin was responsible for breakthrough bleeding or spotting in 4.7% of the cases; the figure was 10.4% for Rigevidon. Anteovin-induced breakthrough bleeding occurred only in the 1st cycle; the incidence of this side effect calculated for the number of cycles was only 1.04%. 14 very young women suffered from algomenorrhea hypermenorrhea premenstrual tension before taking the tablets. These anomalies stopped from the 2nd cycle during Anteovin treatment. In women discontinuing the use of tablets because they wanted a child it could be observed that after stopping the 3-6 month contraceptive treatment conception occurred already in the 1st month after Anteovin consumption. It occurred only after a 2-3 month interval after the discontinuation of monophasic products. In the over 35 age group the cycle regulatory effect of Anteovin could be observed.